Allurion Technologies Price to Free Cash Flow Ratio 2021-2025 | ALUR

Allurion Technologies price to free cash flow ratio from 2021 to 2025. Price to free cash flow ratio can be defined as

Allurion Technologies Price to Free Cash Flow Ratio 2021-2025 | ALUR

Allurion Technologies price to free cash flow ratio from 2021 to 2025. Price to free cash flow ratio can be defined as
Related Stocks
Company NameMarket
Cap
Abbott Laboratories (ABT)$229.2B
Boston Scientific (BSX)$152.7B
Stryker (SYK)$149.2B
EssilorLuxottica (ESLOY)$131.9B
Medtronic (MDT)$115.1B
Lonza Group Ag (LZAGY)$50.1B
Haleon (HLN)$43.5B
ResMed (RMD)$37.3B
GE HealthCare Technologies (GEHC)$34.5B
Agilent Technologies (A)$32.2B
Terumo (TRUMY)$24.4B
Koninklijke Philips (PHG)$23.5B
Insulet (PODD)$20.3B
Zimmer Biomet Holdings (ZBH)$18.6B
Baxter (BAX)$14.6B
Smith & Nephew SNATS (SNN)$13B
Sunny Optical Technology (SNPTF)$10.4B
Demant (WILYY)$8.6B
Bio-Rad Laboratories (BIO)$6.7B
Lantheus Holdings (LNTH)$5.1B
Perrigo (PRGO)$3.7B
Prestige Consumer Healthcare (PBH)$3.7B
Haemonetics (HAE)$3.6B
Shandong Weigao Medical Polymer (SHWGF)$3.5B
Envista Holdings (NVST)$3.3B
ICU Medical (ICUI)$3.1B
LeMaitre Vascular (LMAT)$1.9B
QuidelOrtho (QDEL)$1.9B
AtriCure (ATRC)$1.5B
Acuren (TIC)$1.4B